Nexentis unit MitoCareX Bio generates optimized hit molecule in MITOLINE drug program

• Nexentis said wholly owned unit MitoCareX generated an optimized hit molecule with improved pharmaceutical properties versus its initial hit compound, marking its first drug-discovery milestone since Nexentis acquired the business.
• Work targets a mitochondrial SLC25 carrier protein, with development aimed at oncology and inflammatory metabolic disease indications.
• Nexentis said MITOLINE, its algorithm platform, enabled 3D structural modeling used to identify the initial hit molecule, which has now been advanced through medicinal-chemistry optimization.
• MitoCareX is moving toward lead selection ahead of pre-clinical trials.
• Nexentis said it controls about 98% of Save Foods, which focuses on post-harvest treatment technologies to reduce pathogen contamination in fruits and vegetables.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexentis Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605130707PRIMZONEFULLFEED9719351) on May 13, 2026, and is solely responsible for the information contained therein.